Blog

Portal Bio's March 2026 newsletter is live, featuring five new experimental datasets across immune cell engineering, live-cell drug discovery assays, and high-throughput automated screening. Each experiment demonstrates a workflow that conventional electroporation and lipid nanoparticle methods cannot reliably replicate in primary immune cells.

Portal delivers circular RNA (circRNA) directly into cells, enabling protein expression lasting up to 10 days and simultaneous co-delivery of multiple constructs in a single step. In collaboration with Massachusetts General Hospital, circRNA-engineered CAR-T cells achieved 75+% dual positive co-expression of CD19 CAR and membrane-bound IL-12, with 95% tumor cell cytotoxicity at a 3:1 effector-to-target ratio.